Edwards Lifesciences Corporation
- Open
- 91.08
- Day high
- 91.61
- Day low
- 89.33
- Prev close
- 90.82
- Volume
- 426K
- Mkt cap
- $51.7B
- P/E (TTM)
- 51.6
- EPS (TTM)
- $1.74
- P/B
- 4.9
- P/S
- 7.9
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$4.6M over the last 3 months (0 open-market buys, 12 sales)
- 🏛Institutions mixed (13F)
Edwards Lifesciences Corporation (EW) is a Healthcare company listed on NYSE. The stock is up 13% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 12 sales (SEC Form 4). Drillr has 1 published research article covering EW.
Edwards Lifesciences Corporation (EW) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 9 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
EW earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 23, 2026 | $0.74 | $0.78 | +5.0% | $1.7B | +2.4% |
| Apr 23, 2026 | $0.73 | $0.78 | +7.0% | $1.6B | +3.2% |
| Oct 30, 2025 | $0.60 | $0.67 | +12.4% | $1.6B | +3.7% |
| Jul 24, 2025 | $0.62 | $0.67 | +7.4% | $1.5B | +3.0% |
| Apr 23, 2025 | $0.60 | $0.64 | +7.4% | $1.4B | +0.9% |
| Oct 24, 2024 | $0.67 | $0.67 | +0.8% | $1.4B | -12.3% |
| Jul 24, 2024 | $0.69 | $0.70 | +1.4% | $1.4B | -16.2% |
| Apr 25, 2024 | $0.64 | $0.66 | +3.1% | $1.6B | +1.8% |
| Feb 6, 2024 | $0.64 | $0.64 | +0.0% | $1.5B | +2.7% |
| Oct 25, 2023 | $0.59 | $0.59 | +0.0% | $1.5B | +0.1% |
| Jul 26, 2023 | $0.65 | $0.66 | +1.5% | $1.5B | +1.8% |
| Jan 31, 2023 | $0.61 | $0.64 | +4.9% | $1.3B | +1.1% |
EW insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 31, 2026 | Dahl Andrew M.officer: SVP, Corporate Controller | Sell | 544 | $91.06 |
| Aug 28, 2026 | Bruls Annetteofficer: CVP, EMEACLA | Sell | 2,644 | $89.98 |
| Aug 26, 2026 | Chopra Daveenofficer: CVP, TMTT, Surgical & IHFM | Option | 31,800 | $72.68 |
| Aug 26, 2026 | Chopra Daveenofficer: CVP, TMTT, Surgical & IHFM | Sell | 1,154 | $91.76 |
| Aug 26, 2026 | Markowitz Wayneofficer: CVP, JAPAC | Sell | 1,240 | $91.47 |
| Aug 26, 2026 | Chopra Daveenofficer: CVP, TMTT, Surgical & IHFM | Sell | 30,646 | $90.99 |
| Aug 11, 2026 | Lippis Daniel J.officer: CVP, TAVR | Sell | 619 | $92.03 |
| Aug 11, 2026 | Lippis Daniel J.officer: CVP, TAVR | Option | 619 | $72.68 |
| Jul 30, 2026 | Markowitz Wayneofficer: CVP, JAPAC | Sell | 146 | $86.03 |
| Jul 28, 2026 | Markowitz Wayneofficer: CVP, JAPAC | Option | 9,628 | $74.02 |
| Jul 28, 2026 | Markowitz Wayneofficer: CVP, JAPAC | Sell | 9,628 | $85.06 |
| Jul 27, 2026 | Zovighian Bernard Jdirector, officer: CEO | Sell | 2,921 | $83.93 |
| Jul 13, 2026 | Bruls Annetteofficer: CVP, EMEACLA | Tax | 109 | $92.21 |
| Jul 10, 2026 | Lippis Daniel J.officer: CVP, TAVR | Option | 619 | $72.68 |
| Jul 10, 2026 | Mistras Theodoraofficer: CVP, Chief Financial Officer | Grant | 12,325 | — |
Source: EW SEC Form 4 filings, latest Aug 31, 2026. For informational purposes only — not investment advice.
See the full EW insider & 13F page →Edwards Lifesciences Corporation company profile
Overview
Edwards Lifesciences Corporation (NYSE:EW) is a leading medical device company founded in 1958 and headquartered in Irvine, California. The company has evolved from its origins as a division of American Hospital Supply Corporation to become a specialized leader in structural heart disease and critical care monitoring technologies. Edwards went public in 2000 and has since focused increasingly on structural heart therapies, completing the sale of its Critical Care business in 2024 to concentrate solely on treating heart valve diseases and related conditions.
Business
Edwards Lifesciences operates in the medical device industry, specifically focusing on structural heart disease treatments. Structural heart disease refers to problems with the heart's valves and chambers that affect blood flow, often requiring surgical or minimally invasive interventions to repair or replace damaged heart components. The company operates through three primary business segments: 1. Transcatheter Aortic Valve Replacement (TAVR) represents approximately 75% of total revenue and involves minimally invasive procedures to replace diseased aortic heart valves. The flagship product is the SAPIEN family of valves, which can be inserted through a catheter rather than requiring open-heart surgery. This technology serves patients with aortic stenosis, a condition where the heart's aortic valve becomes narrowed and restricts blood flow. 2. Transcatheter Mitral and Tricuspid Therapies (TMTT) accounts for roughly 6% of revenue and includes both repair and replacement technologies for the heart's mitral and tricuspid valves. Key products include the PASCAL repair system for mitral valve disease and the EVOQUE replacement system for tricuspid valve disease. These address conditions where these valves leak or don't close properly. 3. Surgical Structural Heart represents about 18% of revenue and provides traditional surgical heart valve solutions, including the INSPIRIS RESILIA aortic valve and other tissue-based replacement valves used in open-heart surgery procedures. The company recently divested its Critical Care monitoring business to focus exclusively on structural heart therapies, marking a strategic shift toward specialization in heart valve treatments.
Revenue model
Edwards Lifesciences generates revenue primarily through product sales to hospitals and healthcare systems worldwide. The company sells its medical devices directly to hospitals through a dedicated sales force and also uses independent distributors in certain international markets. The business model centers on selling high-value, specialized medical devices that require significant clinical expertise and training. Revenue streams include: 1. Device Sales: The primary revenue driver comes from selling heart valve replacement and repair devices, with TAVR products commanding premium pricing due to their advanced technology and clinical benefits. 2. Recurring Revenue Characteristics: While not subscription-based, the business benefits from the growing prevalence of heart valve disease in aging populations and expanding clinical indications for minimally invasive treatments. Several factors influence the company's margins and profitability. Positive margin drivers include the premium pricing power of innovative technologies, expanding clinical indications that increase addressable patient populations, and operational leverage as procedures become more routine. The company's focus on high-value, differentiated products allows it to maintain strong gross margins typically above 75%. Margin pressures come from healthcare cost containment efforts, competitive pricing dynamics in international markets, and the substantial R&D investments required to develop next-generation therapies. Additionally, hospital capacity constraints and staffing shortages can temporarily limit procedure volumes, affecting revenue growth. Currency fluctuations also impact international sales, and regulatory approval timelines can delay new product launches.
Competitive moat
Edwards Lifesciences possesses a strong competitive moat built on several key advantages. The company benefits from significant regulatory barriers, as heart valve devices require extensive clinical trials and FDA approvals that can take years and cost hundreds of millions of dollars. This creates substantial barriers to entry for new competitors. The company's clinical evidence and physician relationships represent another crucial moat element. Edwards has built decades of clinical data demonstrating the safety and efficacy of its products, and has established deep relationships with cardiac surgeons and interventional cardiologists who require extensive training on these complex procedures. Intellectual property protection through patents provides additional competitive protection, particularly for newer technologies like TAVR and transcatheter mitral/tricuspid therapies. The company's early mover advantage in TAVR has allowed it to build substantial market share and clinical expertise. However, the moat faces potential challenges from well-funded competitors including Medtronic, Abbott, and Boston Scientific, who are investing heavily in competing technologies. The medical device industry also faces ongoing pricing pressure from healthcare systems seeking cost reductions. Additionally, as transcatheter procedures become more standardized, the technical barriers may diminish over time, potentially increasing competitive intensity. The strength of Edwards' moat appears most robust in newer therapy areas like TMTT, where the company is establishing early clinical evidence and market presence, while facing more competitive pressure in the more mature TAVR market.
Risks & safety
Edwards Lifesciences demonstrates a strong financial position with substantial margin of safety indicators: • Liquidity: $3.0 billion in cash and short-term investments with minimal debt (debt-to-equity ratio of 0.07), providing significant financial flexibility • Profitability: Strong operating margins around 27-28% with consistent positive free cash flow generation, though Q4 2024 showed temporary negative free cash flow of -$177 million • Solvency: Current ratio of 4.2x indicates strong ability to meet short-term obligations • Valuation Metrics: Trading at P/E ratio of 28.3x and EV/EBITDA of 21.4x, reflecting premium valuations typical of growth-oriented medical device companies • Growth Trajectory: Consistent revenue growth with 2024 sales of $5.4 billion representing 9% growth • Market Position: Leading market share in TAVR with expanding presence in newer TMTT markets provides defensive characteristics
Recent development
Over the past several years, Edwards Lifesciences has undergone a significant strategic transformation focused on becoming a pure-play structural heart company. The most notable move was completing the sale of its Critical Care business to Becton Dickinson, allowing management to concentrate resources entirely on heart valve therapies. The company has pursued an aggressive acquisition strategy to expand its structural heart portfolio, acquiring JC Medical, JenaValve (for aortic regurgitation treatment), and Endotronix (for heart failure management). These acquisitions represent Edwards' expansion beyond traditional valve replacement into adjacent structural heart conditions. Product development milestones include the successful launch of the EVOQUE tricuspid valve replacement system, which received FDA approval and represents the first transcatheter treatment for tricuspid regurgitation. The company is also preparing for the launch of SAPIEN M3 for mitral valve replacement, expecting European approval in mid-2025. A major clinical catalyst is the pending Early TAVR trial results, which could expand TAVR treatment to asymptomatic patients with severe aortic stenosis. FDA approval for this indication is expected in mid-2025 and could significantly expand the addressable patient population. The company has also invested heavily in its TMTT portfolio, with the PASCAL repair system and EVOQUE replacement system driving 77% growth in this segment during 2024, reaching $352 million in annual sales.
EW company profile · for informational purposes only — not investment advice.
Track EW with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free